Endothelin expression and the progression of heart failure - Exemplifying the vagaries of therapeutic development

被引：13

作者：

Konstam, MA

DeNofrio, D

机构：

[1] Tufts Univ New England Med Ctr, Div Cardiol, Dept Med, Boston, MA 02111 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

CIRCULATION | 2004年 / 109卷 / 02期

关键词：

heart failure; endothelin; renin; angiotensin;

D O I：

10.1161/01.CIR.0000110644.92116.91

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：143 / 145

页数：3

共 19 条

[1] Chronic oral endothelin type A receptor antagonism in experimental heart failure [J].

Borgeson, DD ;

Grantham, JA ;

Williamson, EE ;

Luchner, A ;

Redfield, MM ;

Opgenorth, TJ ;

Burnett, JC .

HYPERTENSION, 1998, 31 (03) :766-770

[2] Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].

Dargie, HJ ;

Colucci, Y ;

Ford, I ;

Sendon, JLL ;

Remme, W ;

Sharpe, N ;

Blank, A ;

Holcslaw, TL .

LANCET, 2001, 357 (9266) :1385-1390

[3] COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].

FRANCIS, GS ;

BENEDICT, C ;

JOHNSTONE, DE ;

KIRLIN, PC ;

NICKLAS, J ;

LIANG, CS ;

KUBO, SH ;

RUDINTORETSKY, E ;

YUSUF, S .

CIRCULATION, 1990, 82 (05) :1724-1729

[4]

Hjalmarson Å, 1999, LANCET, V353, P2001

[5] Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [J].

Kalra, PR ;

Moon, JCC ;

Coats, AJS .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) :195-197

[6] EFFECTS OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL ON THE LONG-TERM PROGRESSION OF LEFT-VENTRICULAR DILATATION IN PATIENTS WITH ASYMPTOMATIC SYSTOLIC DYSFUNCTION [J].

KONSTAM, MA ;

KRONENBERG, MW ;

ROUSSEAU, MF ;

UDELSON, JE ;

MELIN, J ;

STEWART, D ;

DOLAN, N ;

EDENS, TR ;

AHN, S ;

KINAN, D ;

HOWE, DM ;

KILCOYNE, L ;

METHERALL, J ;

BENEDICT, C ;

YUSUF, S ;

POULEUR, H .

CIRCULATION, 1993, 88 (05) :2277-2283

[7] Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors [J].

Love, MP ;

Haynes, WG ;

Gray, GA ;

Webb, DJ ;

McMurray, JJV .

CIRCULATION, 1996, 94 (09) :2131-2137

[8] Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure -: The heart failure ETA receptor blockade trial (HEAT) [J].

Lüscher, TF ;

Enseleit, F ;

Pacher, R ;

Mitrovic, V ;

Schulze, MR ;

Willenbrock, R ;

Dietz, R ;

Rousson, V ;

Hürlimann, D ;

Philipp, S ;

Notter, T ;

Noll, G ;

Ruschitzka, F .

CIRCULATION, 2002, 106 (21) :2666-2672

[9] INCREASED ENDOTHELIN IN EXPERIMENTAL HEART-FAILURE [J].

MARGULIES, KB ;

HILDEBRAND, FL ;

LERMAN, A ;

PERRELLA, MA ;

BURNETT, JC .

CIRCULATION, 1990, 82 (06) :2226-2230

[10] Role of endogenous endothelin in chronic heart failure - Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling [J].

Mulder, P ;

Richard, V ;

Derumeaux, G ;

Hogie, M ;

Henry, JP ;

Lallemand, F ;

Compagnon, P ;

Mace, B ;

Comoy, E ;

Letac, B ;

Thuillez, C .

CIRCULATION, 1997, 96 (06) :1976-1982

← 1 2 →